Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Paul Kelly who wrote (1297)	2/22/1999 9:39:00 PM
From: Dan Spillane	Read Replies (1) \| Respond to of 2539

I also think this poor sucker in Brazil is in for more trouble than he bargained for, because this will turn into a real thorny trade issue, involving things way over his head, and he is not the federal government. I suspect there will be some kind of retraction, or he will be ousted. It's really odd to see state (rather than federal) news making headlines on an issue involving world trade. It makes me think this guy was put up to this by Greenpeace, et al.

To: Paul Kelly who wrote (1297)	2/22/1999 9:41:00 PM
From: Bindusagar Reddy	Read Replies (1) \| Respond to of 2539

Well said. This hysteria is definitely the work of FLAT EARTH SOCIETY. They hate science and scientific advances. It is hard to believe in 1999 we have to deal with people like this..But 2000 might be psychologically start a new century with new thinking. 21 st Century will be dominated by Genetic advances and communication advances. BR

To: Paul Kelly who wrote (1297)	2/22/1999 9:52:00 PM
From: Bindusagar Reddy	Respond to of 2539

Analyst Sees Celebrex Hitting $1B In Sales In First Yr By THOMAS BURTON Dow Jones Newswires CHICAGO -- A leading health-care analyst told Dow Jones that, based on the latest sales numbers, it now is "conservative" to predict that the Monsanto Co. (MTC) arthritis-pain drug Celebrex will hit $1 billion in sales in its first year on the market. Meanwhile, those sales figures for Celebrex's fifth week on the market show that it is closing in on the sales of impotence medication Viagra at a comparable time. Since Viagra is the No. 1-selling recent drug in achieving early sales, this means that Celebrex could easily become the all-time early top-seller among recent drugs, said the analyst, Hemant K. Shah. "At this point, it is conservative to say Celebrex will be a billion-dollar drug in its first year," said Shah. NDC Health Information Services, which supplies marketing data to the pharmaceutical industry, told Dow Jones that Celebrex sales for the fifth week of marketing, ended Sunday Feb. 21, hit 155,000 prescriptions. Viagra achieved 310,000 prescriptions at the same point in its marketing history. But NDC's senior vice president, Shel Silverberg, told Dow Jones that the fifth week was the highest single week that Viagra achieved. And Celebrex is running at about five times the early sales of the cholesterol medication Lipitor, which was No. 2 among recent new pharmaceutical products until Celebrex came along. Lipitor hit about 30,000 prescriptions during its fifth marketing week, in 1997, according to Silverberg. Lipitor is projected to be a $3 billion drug this year. Monsanto co-markets Celebrex with Pfizer Inc. (PFE), the maker of Viagra and also the co-marketer of Warner-Lambert Co.'s (WLA) Lipitor. The joint marketing of Celebrex truly starts only this week, with sales just beginning. Yet without such "detailing" visits to doctors, Celebrex already has grabbed about 16% of the pain treatment market, Shah said. Celebrex is the forerunner of a new class of arthritis drugs known as Cox-2 inhibitors. They act against an enzyme called cyclooxygenase-2, or Cox-2 for short. The Cox-2 drugs have special promise, in the view of many rheumatologists and internists, because clinical data suggest that these medications may not cause damage to patients' gastrointestinal tracts, as current drugs do. The next Cox-2 drug likely to be approved by the Food and Drug Administration is Merck & Co.'s (MRK) Vioxx. - Thomas Burton; 312-750-4123 Briefing Book for: MTC \| PFE \| WLA